NFKB1 and Hepatic fibrosis: Compared to the positive control group, treatment of RBO at both dosage levels (0.2 and 0.4 mL/rat) for two weeks after development of liver fibrosis made a considerable reduction in liver content of TNF-α, IL-1β, and NF-κβ.